Anti-tumour therapeutic efficacy of OX40L in murine tumour model by Ali, SA et al.
 Anti-Tumour Therapeutic Efficacy Of OX40L in Murine Tumour Model  
Selman A. Ali, * Murrium Ahmad,* June Lynam, Cornelia S. McLean, † Claire 
Entwisle, † Peter Loudon, † Esther Choolun, * Stephanie E. B. McArdle, * Geng Li, * 
Shahid Mian, * and Robert C. Rees * 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*School of Science, Nottingham Trent University, Clifton Lane, Nottingham NG11 8NS, UK; 
and the †Xenova Group plc, Cambridge Science Park, Cambridge CB4 4GN, UK. 
1This work was supported by Xenova Pharmaceuticals, The Thomas Farr Charity, The John and 
Lucille van Geest Foundation, The Dowager Eleanor Peel Trust and The Cancer and Polio 
Research Fund. 
 
Correspondence To: 
Robert C Rees  
Professor of Biomedical Science 
Department of Life Sciences, The Nottingham Trent University 
Clifton Lane, Nottingham NG11 8NS 
Tel:  + 44 0115 8486342 
Fax:  + 44 0115 8483384 
Eml:  robert.rees@ntu.ac.uk 
 
 
 
 
 
 
 
 
 
 
 
 2
Abstract 
The OX40 ligand (OX40L), a member of TNF superfamily, is a costimulatory molecule 
involved in T cell activation. It is expressed on antigen presenting cells including dendritic 
cells (DC) and activated B cells. This molecule has been reported to provide potent 
costimulation in APC-T cell interactions upon binding to its cognate receptor, OX40 which is 
expressed by activated T cells. In this study systemic administration of OX40L fusion protein 
was used in the treatment of established murine subcutaneous colon and breast carcinomas. 
Intra-peritoneal injection of mOX40L fusion protein significantly inhibited the growth of 
subcutaneous 3 day established colon (CT26) and breast (4T1) carcinomas which was dose 
and route dependent. Effective therapy with OX40L required the the presence of tumour for 3 
days prior to OX40L, concomitant therapy, given at the same time (day 0) as tumour cells 
was less effective. Furthermore, therapy with OX40L fusion protein was effective in 
significantly reducing CT26 experimental lung metastasis. In addition, inhibition of CT26 
and 4T1 tumours in response to therapy with OX40L was significantly enhanced by 
combination treatment with intra-tumour injection of a DISC-HSV vector encoding mGM-
CSF. Tumour rejection in response to OX40L therapy was correlated with splenocyte CTL 
activity against the gp70 CT26 tumour associated antigen. In vivo depletion studies 
demonstrated the requirement for both CD4+ and CD8+ T cells for effective OX40L therapy. 
Collectively these results demonstrate the potential role of the OX40L in cancer 
immunotherapy. 
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 Introduction 
T cells play an important role in immunological surveillance and eradication of cancer, and 
their activation requires at least two signals (Bretscher, et al 1992; Carreno and Collins 2002). 
The first signal is delivered through the T-cell receptor (TCR) via the antigen-specific 
recognition and binding to MHC/ peptide complex; this triggers the T cell activation cycle 
but is insufficient for the generation of effector function, which requires a second co-
stimulatory signal to promote cytokine production and proliferation.  This complex series of 
events is mediated through the interaction of surface molecules (ligands/receptors) on APC 
and their counterparts on the surface of T cells (Guinan et al, 1994; Hellstrom et al, 1996). 
There are a number of molecules normally expressed on the surface of antigen presenting 
cells (APC) that perform co-stimulatory functions by interacting with their counter 
ligand/receptor on T cells to provide the critical second signal for T-cell and/or APC 
activation including: CD80 (B7-1) / CD86 (B7-2) binding to CD28 and CTLA4 respectively; 
CD40L on activated CD4 helper cells binding to CD40 receptors on APCs; human CD58 and 
mouse CD48 (LFA-3) binding to CD2; and CD54 (ICAM-1) binding to LFA-1. Failure to 
provide secondary co-stimulation can cause T cell anergy, a form of non-responsiveness 
resulting from incomplete T cell activation (Croft et al, 1997).  Furthermore generating CD8+ 
T-cell effector cells requires a CD4+ T-helper (Th) response, mediated principally by MHC 
restricted Th1 cells.  The generation of these effector cells requires not only TCR-MHC 
peptide interaction, but also secondary signals that mediate cell survival (Oh etal, 2003). 
 
 Therefore the level of co-stimulation has a profound effect on the response to antigens, and 
strong co-stimulatory signal can convert a weak agonist into a full agonist and an agonist into 
a super-agonist (Murtaza etal, 1999). Co-stimulatory interactions can also play a crucial role 
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during the death phase of the T cell response and determine the number of effector T cells 
that survive to become memory T cells (Bansal-Paskala etal, 2001). Several members of the 
TNF R super-family including CD27, CD30, 4-1BB and OX40 have also been shown to 
transmit a co-stimulation signal for CD8+ and CD4+ T cell proliferation, cytokine production 
and cell survival in a manner similar to that of CD28 (Smith etal,1994, cell 76, 959; Gruss 
and Dower, 1995, blood, 85, 3378). 
Improving cancer immunotherapy approaches requires an understanding of the molecular 
interactions responsible for inducing anti-cancer T cell responses. The availability of well-
characterised tumour associated antigens "TAAs" combined with our knowledge of the 
requirements for T-cell activation allows us to propose new strategies for cancer vaccine 
based therapy.  One important signal influencing T-helper cell activation is mediated via the 
OX40 pathway. 
The OX40 receptor (CD134) is a membrane bound glycoprotein belonging to the tumour 
necrosis factor (TNF) receptor superfamily and recent evidence suggests that this ligand - 
receptor pathway is important for promoting the full effector function of CD4+ T - helper 
cells (Weinberg et al, 2000). OX40 Ligand (OX40L) is a type II transmembrane protein and 
is expressed on B cells, dendritic cells (DCs) and endothelial cells (Stuber etal, 1995; Imura 
et al, 1996). Signals transmitted via CD28 and OX40 are highly synergistic for CD4+ T cell 
proliferation and survival (Gramaglia et al, 1998), and interaction of OX40L with its receptor 
(CD134) has been shown to increase the expansion and survival of naïve CD4+ T cells, and to 
enhance memory Th cell survival by inhibiting peripheral deletion (Maxwell et al, 2000 J; 
Gramaglia et al, 2000). Modulating the OX40-OX40L pathway can influence the in vivo 
pathogenesis of infection and cancer. Altering the Th1/ Th2 balance by administering anti-
OX40 L mAb abrogates progressive Leishmaniasis in susceptible Balb/c mice, which was 
associated with reduced production of Th2 cytokines (Akiba et al, 2000). In animal tumour 
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models, in vivo ligation of OX40R by administration of OX40L:immunoglobulin fusion 
protein or OX40R mAb resulted in a significant prolongation of survival of tumour-bearing 
mice in four histologically distinct tumour models (Weinburg et al, 2000). The therapeutic 
efficacy of OX40 mAb was influenced by the tumour burden, the site of tumour growth and 
the intrinsic immunogenecity of the tumour  (Kjaergaard et al, 2000).   Furthermore, OX40+ 
Th cells have been detected in human breast, melanoma and head and neck cancer tissue 
(Vetto etal, 1997). 
In the present study, the role of OX40L as a co-stimulatory molecule for cancer therapy was 
further analysed. Intraperitoneal administration of OX40L-immunoglobulin conjugates to 
tumour-bearer animals inhibited tumour growth in a dose and time dependent manner. The 
inhibition was shown to correlate with splenocytes CTL activity and in vivo depletion of 
CD4+ and CD8+ T cells abrogated antitumour activity.   This study also demonstrated that 
therapy with OX40L fusion protein combined with direct intra-tumour injection with a 
disabled single cycle herpes simplex virus encoding the gene for murine granulocyte - 
mecrophage colony stimulating factor (DISC-mGM-CSF) enhanced the therapeutic response 
and  induced maximum tumour growth inhibition. 
 
Materials and Methods 
Animals   
Female Balb/c mice were purchased from Harlan (UK) Ltd, and maintained in accordance with 
the Home Office Codes of Practice for housing and care of animals. 
 
Peptides  
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A known murine leukemia virus (MuLV) gp-70 derived H2Ld restricted peptide AH-1 
(SPSYVYHQF, 138-147) and a control β-galactosidase H2Ld restricted peptide (TPHPARIGL, 
877-88) were synthesised  (Company) and used for in vitro assays. 
 
Cell lines and Tumour Therapy Protocols 
  The CT26 cell line is a N-nitroso-N-methylurethane induced Balb/c murine colon carcinoma, 
maintained by serial in vitro passage in DMEM tissue culture media supplemented with 2mM L-
glutamine and 10% FCS. This cell line was provided by Prof Ian Hart, (ICRF, London, UK).  
The A20 Balb/c murine B cell lymphoma, RENCA (a balb/c renal cell carcinoma line) and the 
NK sensitive YAC-1 lymphoma were maintained by serial in vitro passage in RPMI 1640 tissue 
culture media supplemented with 2mM L-glutamine, 10% FCS and 0.05mM 2-Mercaptoethanol. 
Subcutaneous (s.c) CT26 and 4T1 tumours were induced by the injection of 1x104 cells on the 
right flank. Ten animals per group were injected intra-peritoneally or as indicated for individual 
experiment at times / intervals after tumour cell implantation with OX40L conjugated protein or 
media in a volume of up to 300μl. For combination therapy experiments, animals were injected 
s.c with 8-104 to 1x105 tumour cells; mice with tumors of a size of 0.09-0.36 cm2 diameter were 
selected at 8-10 days. Intra-tumour therapy was performed by directly injecting DISC/-
HSV/mGM-CSF virus (50μl volume) into the tumour followed by intra-peritoneal OX40L 
fusion protein injection; the dose of vector and time of administration is shown for individual 
experiments.  Statistical analysis was performed using Graph Pad Software (Student t test and ). 
 
DISC/mGMCSF viral vector  
DISC/mGM-CSF-HSV (dH2B) was constructed by recombination as previously described (Ali, 
etal, 2000; Todryk, et al, 1999). The DISC/mGM-CSF virus (dH2B) is thymidine kinase 
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negative (TK-), gH negative (gH-) and expresses murine granulocyte-macrophage-colony 
stimulating factor (mGM-CSF) following infection of normal or complementing cells. 
 
OX40L Preparation 
The MM1 (murine OX40L-murine IgG1) and MH1 (murine OX40L-human IgG1) are hybrid 
proteins constructed by linking the appropriate truncated murine or human immunoglobulin 
gamma 1 gene (hinge-CH2-CH3) to the extracellular domain (aa50-198) of the murine OX40 
ligand gene (Genbank U12763). The linkage is achieved via a mutated heterologous hinge 
region, which is identical to the native sequence except that the cysteine residues have been 
changed to alanine in order to increase the flexibility of the linkage. The fused polypeptides 
are designed as secreted products which are achieved by use of a signal sequence from the 
murine B72.3 antibody (Whittle etal, 1987) ligated at the NH2 terminal.  
The MM1 and MH1 proteins were produced in stable transfected Chinese Hamster Ovary 
(CHO) cells (Lonza Biologicals, UK) grown in hollow fibre or roller bottle culture in serum 
containing media. The growth media was purified on a protein G sepharose column and the 
final product was dialysed against PBS (pH7.4).  
In Vitro Generation of CTL and chromium release cytotoxicity assay 
Spleens were harvested from tumour bearer mice receiving therapy (test) and non-treated 
normal mice (control). Cells were flushed from the spleen (lymphocyte fraction) with serum 
free RPMI media using a 25g needle and syringe. The remaining spleen tissue was cut into 
four pieces, digested with 2ml of enzyme cocktail (1.6 mg/ml collagenase and 0.1% DNase in 
serum free RPM1 media, Sigma, UK) at 37°C in a 5% CO2 in air humidified atmosphere, for 
60 minutes. The spleen tissue was then dissociated by gentle pipetting. The cells 
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(parenchymal fraction) were collected, washed twice in serum free medium, mixed with the 
lymphocyte fraction and suspended in CTL media and cultured at a concentration of 5 x 106 
cells/2ml (RPMI 1640 supplemented with 1% glutamine, 10% FCS, 20mM HEPES, 50 μM 
2ME, 50 U/ml penicillin, 50 μg/ml streptomycin and 0.25 μg/ml fungizone) with 10μM of 
the relevant peptide in to 24 well plates at 2ml / well for 5 days. 
On day 5 of in vitro stimulation, splenocytes were harvested, washed twice in serum free 
media, re-suspended in CTL media, counted and used as effector cells. Target cells were 
harvested by trypsinisation, washed, and labeled with chromium-51.  A standard 4 hours Cr - 
release assay was performed and the percentage specific cytotoxicity was determined using 
the following equation: -  
% Specific Cytotoxicity = (Experimental Release - Spontaneous Release) / (Maximum 
Release - Spontaneous Release) x 100 
 
CD4+ and CD8+ T-cell depletion 
The in vivo depletion of CD4+ and CD8+ was carried out as previously described (Ali et al, 
2000). Briefly, Groups of 10 mice were given three i.p injections of 400 μg of anti-CD4+ 
(YTS191.1.2), anti-CD8+ (YTS169.4.2.1), control isotype antibody (YTH24), or a 
combination of anti-CD4+ and anti-CD8+ antibodies over a period of one week.  
Results 
In vitro T Cell Proliferation in Response to OX40L and OX86 
The effect of murine OX40L and anti-murine OX40 antibody (OX86) on T cell proliferation 
was tested by bioassay in vitro. Balb/c mice were immunised with Staphylococcal 
enterotoxin B (SEB) i.p. and twenty four hours later lymph nodes were removed and 
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processed and their lymphocytes were cultured in vitro with 0.5 μg /ml SEB and varying 
concentrations of murine OX40L (mOX40L), OX86, murine IgG1 or human OX40L 
(Hox40L) for 72 hours. Cells were pulsed with 3H thymidine for the final 6 hours of culture. 
The results (Fig 1) clearly demonstrates that both m OX40L and OX86 but not control human 
OX40L and murine IgG1, enhanced T cell proliferation in a dose dependent manner. Murine 
OX40L stimulated T cell proliferation at 0.001 μg /ml whereas OX86 required 1000 fold 
more protein to induce similar levels of proliferation. 
OX40L Therapy 
It has previously been shown that engagement of OX40 receptors with antibody agonist or 
the OX40L delivers a potent co-stimulatory signal to effector T cells  (Pan etal, 2002; Morris 
etal, 2001). In the present study, the therapeutic effect of systemic administration of mOX40L 
fusion protein into CT26 tumour bearer animals was investigated. Intraperitoneal injection of 
mOX40L protein 3 days after the subcutaneous injection of 1x104 CT26 cells (X10 TD50) 
induced a significant (p=<0.05) inhibition of tumour growth (Fig 2). Similarly, significant 
tumour inhibition (p=<0.01) was obtained using this protocol to treat 4T1 tumour -bearer 
mice. Three and five out of the10 treated animals injected with CT26 and 4T1 tumours cells 
respectively remained tumour free throughout the period of the experiment, and these mice 
remained immune to subsequent subcutaneous challenge with parental tumour cells (data not 
shown). The therapeutic effect of mOX40L was species specific since the human hOX40L 
conjugated to human IgG1 failed to inhibit tumour growth (Fig 3). 
The tumour growth inhibitory effect of mOX40L therapy was shown to be dose and route 
dependent (Fig 4 A&B). Using the 4T1 tumour model, increasing the dose of mOX40L 
administered i.p from 5x100 to 5x250 μg per mouse increased the degree of tumour growth 
inhibition and increased the overall survival (from 3/10 to 6/10 for mice receiving 5x100 and 
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5x250 μg per mouse respectively). Similarly the i.p therapeutic efficacy of mOX40L have 
been increased when the dose was increased from 2x250 μg to 2x500 μg per mouse despite 
the administration frequency decreased from 5 to 2 (Fig  4 A ). Results shown in Fig 4 B 
clearly demonstrates a significant difference (P = <..........) in efficacy between the i.m versus 
the i.p route of administering of mOX40L; five doses of 100μg and 250μg mOX40L given 
i.m reduced tumour growth and tumour incidence in this model compared with mice 
receiving i.p. injections of OX40L. [Selman - needs clarification]. We also observed that the 
murine mOX40L fusion protein was comparable to the anti-murine OX40 (OX86) at 
reducing 4T1tumour growth when administered at equivalent concentrations (data not 
shown). 
Both OX40 and its ligand are upregulated during CD4+ T-cell priming and it was reported 
that expression of OX40 on T cells in the T cell zone in lymph nodes was maximal 3 days 
after antigen administration (Stuber & Strober 1996, j exp med 183, 979).  Based on these 
observations we undertook experiments to establish whether the timing of mOX40L fusion 
protein administration after tumour implantation affected the therapeutic response. The 
results in Fig 5 clearly show that a priming period of 3 days with CT26 tumour cells was 
required to obtain the maximal anti-tumour inhibitory effect with mOX40L (p<0.01). Seven 
out of 10 animals remained tumour free when 100μg of mOX40L fusion protein was injected 
on day 3 compared with 0/10, 1/10, 0/10 and 1/10 for control mice injected with PBS or 
OX40L on day 0, 6 and 10 respectively. 
Effect of mOX40L fusion protein Therapy on Experimental Metastasis 
Experimental lung metastasis was induced by injecting 1x104 CT26 cells intravenously and 
based on the results shown in Fig 5. Treatment with OX40L was started on day 3: control 
mice were given 5 injections of 200µl PBS i.p at 3 days intervals, the remaining 3 groups 
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were given 5 injections of either 50, 100 or 250 µg mOX40L fusion protein i.p, respectively. 
Tumour inhibition was shown to be mOX40L dose dependent; 50% of animals treated with 5 
injections of 250 µg OX40L fusion protein remained tumour free for the duration of the 
experiment in comparison to 33% for groups treated with 50 or 100µg of mOX40L fusion 
protein (Fig 6). Similar results were obtained when the OX40L fusion protein was injected 
intramuscularly (results not shown).  
Combination Therapy of OX40L and DISC/mGM-CSF virus. 
We have previously shown that direct intra-tumour injection of subcutaneous CT26 tumours 
with DISC/mGM-CSF induces the complete regression of tumours in a proportion of treated 
animals (Todryk et al, 1999; Ali et al, 2002). In the present investigation the effect of 
combination therapy of mOX40L fusion protein and DISC/mGM-CSF therapy on established 
subcutaneous 4T1 and CT26 tumours was determined. 4T1 and CT-26 tumours were 
established by s.c. injection of 1-2 x 105 tumour cells, and therapy was administered on day 8 
when tumours were 0.09-0.36 cm2 diameter. The results for 4T1 tumours is given in Fig. 7A. 
Two direct injections of 1.7x107 pfu of DISC-HSV-mGM-CSF at 2 day intervals or intra-
peritoneal injection of 2x250µg of mOX40L fusion protein resulted in tumour growth 
inhibition but no complete tumour regressions were detected. However, a significant increase 
in tumour growth inhibition was observed in mice receiving direct intra-tumour injection of 
DISC/mGM-CSF followed by i.p injection of the mOX40L fusion protein (see Materials and 
Methods for details). Six out of the ten animals treated with combined therapy survived and 
remained tumour free (p=<0.01), and rejected a further challenge with parental 4T1 cells 
(results not shown). Similar results were observed when mice with subcutaneous CT26 
tumours were treated with combination DISC-HSV-mGM-CSF and mOX40L fusion protein 
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(Fig 7B); 3/10, 7/10 and 10/10 mice rejected their tumour following therapy with DISC, 
OX40L and DISC+OX40L, respectively compared with control mice 
CTL Activity in Response to Therapy with OX40L 
To elucidate the potential role of cytotoxic T-lymphocytes (CTL) in tumour rejection induced 
by mOX40L infusion protein therapy, a series of experiments were undertaken to assess the 
presence of CTL activity in CT26 tumour bearer mice treated with mOX40L. The H2-Ld -
restricted AH-1 peptide of the gp70 tumour antigen is endogenously expressed by CT26 
tumour cells and represents an appropriate target peptide for assessing the MHC class I 
restricted CTL response. Splenocytes were harvested from mice that had rejected 
subcutaneous CT26 tumours following i.p injections of the mOX40L fusion protein and mice 
that failed therapy. Splenocytes were cultured for 5 days in the presence of the AH-1 peptide 
(SPSYVYHQF) and assayed for cytolytic activity against CT26 cells, A20 pulsed with the 
AH-1 peptide and YAC-1 cells; the immunogenic TPHPARIGL peptide derived from the 
bacterial protein β-galactosidase was used as an irrelevant control peptide. Spleen cells from 
all test mice (five out of five) that had rejected CT26 tumours in response to therapy with 
mOX40L fusion protein exhibited significant (P<0.001) CTL activity against CT26 and A20 
cells pulsed with the AH-1 peptide (Fig 8 A&B). The average cytolytic activity (at 50:1, E:T 
ratio) of splenocytes responding to the SPSYVYHQF peptide was 60% and 72% against 
CT26 and A20 AH-1 peptide pulsed cells, respectively. The CTL response was peptide 
specific since lymphocytes from the same mice cultured for 5 days with the irrelevant peptide 
(β-gal: TPHPARIGL) were not cytotoxic for CT26 or A20 peptide pulsed target cells  (Fig 8 
A&B). However, only one in four mice with progressor tumours exhibited a low but 
significant CTL activity (data not shown). 
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To confirm the involvement of CD4+ and CD8+ T lymphocytes in the tumour rejection 
resulting from mOX40L fusion protein therapy, mice were depleted of the respective T cell 
population by administration of monoclonal antibodies against either CD4 or CD8 antigens 
(see materials and methods). Four days after the initiation of the antibody treatment, mice 
were injected s.c with 1x104 CT26 cells and 100 μg of mOX40L fusion protein was given on 
days 3, 6 and 9 following tumour cell injection. The results given in Fig 9 show that mice 
depleted of CD4 or CD8 or both failed to respond to treatment with OX40L fusion protein, 
whereas mice receiving either the isotype control serum or media demonstrated a therapeutic 
response to mOX40 therapy. These results confirm the requirement for CD8+ T-cells in 
mediating an anti-tumour effect and infer that both CD4+and CD8+ T-cells are required for 
effective therapy using mOX40L fusion protein. 
 
Discussion 
OX40-OX40L interactions control primary T cell expansion, regulate the numbers of antigen-
specific T cells, promote the survival of T cells and the size of the memory T cell pool 
(Gramaglia et al, 2000, Bansal-Pakala et al, 2001; Rogers et al, 2001). The implication of 
OX40 in auto-reactive disorders is very well documented in human and animal studies 
(Weinberg et al, 1996), and antibodies directed against the up-regulated OX40 receptors 
(CD134) on activated auto-antigen-specific T cells selectively delete them and reduce auto-
reactive inflammation (Weinberg et.al, 1998). Signaling via OX40 can reverse an already 
established state of tolerance even after the onset of antigen-specific hypo-responsiveness 
suggesting that OX40 represents an appropriate target for therapeutic intervention in a variety 
of diseases (Bansal-Pakala et al 2001), however the role of OX40R/OX40L interaction in the 
immune response to malignancies has only recently been recognised. OX40R over-
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expression was reported in tumour infiltrating lymphocytes and tumour-draining lymph node 
cells from melanoma, breast cancer, colon cancer and head and neck cancer patients, and 
their presence suggested a correlation with overall survival rate (Vetto etal, 1997; Weinberg 
et al, 2000, Petty et al, 2002). Unlike its involvement in autoimmunity where reduced clinical 
signs induced by blocking the OX40R-OX40L interaction or depletion of CD4+ cells, the 
anti-tumour adjuvant properties of the OX40 is based on it’s engagement with its ligand 
during the initiation process of active immunisation, which leads to enhanced cytokine 
production and increased numbers of antigen-specific memory cells (Weinberg, 2002). It was 
proposed that expansion of tumour reactive OX40R+ T cells localising in cancer tissues 
could lead to an increase in tumour-specific immunity (Weinberg et.al, 2000). Furthermore, 
NK cells, for example are known to express OX40L (Kashii et al, 1999), which may on 
ligation enhanced their apoptotic anti-tumour killing.  
In the present study, injecting mOX40L infusion protein into mice bearing moderately or 
poor immunogenic CT26 and 4T1 tumours respectively induced a dose and route dependant 
inhibition of tumour growth. Unlike the results reported by Kjaergaad et al (2000) where anti-
OX40 administration had no impact on the growth of the poorly immunogenic B16/D5 
melanoma, we have shown that both mOX40L and anti OX40R antibody induced significant 
tumour growth inhibition of 4T1 in spite of its poor  immunogenecity. Murine OX40L fusion 
protein was more potent than the anti-OX40 antibody (OX86) in inducing the proliferation of 
T-cells from Staphylococcal enterotoxin B primed Balb/c mice, when used at equivalent 
protein concentrations, however they induced comparable tumour growth inhibition when 
injected i.p into 4T1 tumour bearer mice (data not shown). Why OX86 antibody appears to be 
more effective in vivo is unclear although one possibility is its in vivo functional half-life or 
OX40L/OX40R may have selective affinity towards cells expressing OX40R.  
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Engagement of OX40 during an ongoing immune response has proved to be a potent adjuvant 
that enhances antigen-specific immunity (Weinberg, 2002). CT26 tumour rejection in 
response to therapy with mOX40L was correlated with CTL activity; spleens from all tumour 
regressor, but not tumour progressor mice when cultured with the AH-1 peptide showed a 
potent in vitro CTL activity against CT26 or AH-1 peptide pulsed A20 cells. It has been 
shown that OX40 expression and activation of intestinal intra-epithelial lymphocytes was 
positively correlated with cell-mediated cytotoxicity and IFNγ synthesis (Wang and Klein, 
2001). In the present study, mice that rejected their tumours (regressor) following therapy 
with the mOX40L, remained immune to further challenge with parental tumour cells 
indicating the presence of immunological memory. Furthermore, the in vivo depletion 
experiments clearly demonstrated the requirement for both CD4+ and CD8+ cells in tumour 
rejection in response to therapy with mOX40L fusion protein. Similarly, using OX40R 
monoclonal Ab, the induced GL261 glioma regression in B6 mice was also found to be 
dependent on both CD4+ and CD8+ (Kaergaard et al, 2000). These results are consistent with 
our previous observation that both T-cell populations are involved in tumour rejection 
following therapy of established tumours with DISC/mGM-CSF (Ali et al, 2000, 2002). 
The time of administration of mOX40L following tumour cell implantation clearly has an 
impact on tumour growth; results demonstrate that therapy initiated on day 3 after tumour cell 
injection gave the best anti-tumour effect. Therapy given on days 0, 6 or 10 did not affect 
tumour growth, and correlates with the known in-vitro effects of OX40 signalling on T-cell 
survival and immune response. Three days may be required to activate T cells following 
exposure to antigen, to express OX 40R, which is only expressed by naïve CD4+ T cells 2-3 
days after activation by antigen; OX40R expression then decreases by 4-5 days (Bansal-
Pakala et al, 2001).  Flow cytometry analysis of blood CD4+ and CD3+ T-cells performed 17, 
24 or 72 hours following CT26 tumour implantation did not show a significant increase in 
 16
OX40R expression (data not shown), although it has been reported that unlike naïve T cells, 
the majority of effector T cells up-regulate their expression of OX40R by 4 hours after 
antigen stimulation (Gramaglia et al, 1998).   
 
Primary tumours are frequently cured by conventional therapies, and metastatic lesions often 
do not respond to these treatments or they progress after a period of growth cessation. 
Therefore, the development of vaccine-based therapies for established metastatic disease or 
prophylactic vaccination to prevent the development of latent metastasis would be of great 
value in clinical therapy. In the present study it was shown that i.p injection of mOX40L 
fusion protein 3 days after i.v inoculation of CT26 tumour cells inhibited experimental lung 
metastasis, in a dose dependent manner. This provides further direct evidence that mOX40L 
mediated inhibition of experimental metastasis correlates with reports that engagement of 
OX40 during the tumour-specific adoptive immunotherapy improves the ability of T cells to 
eradicate lung and brain metastasis (Kjaergaard et al, 2001). We further tested the efficacy of 
the mOX40L administration in combination with the intra-tumour injection of DISC/mGM-
CSF virus vector, and have previously reported that intra-tumour injection of established s.c 
tumours with DISC/mGM-CSF induced tumour growth inhibition and complete tumour 
regression in a proportion of treated mice (Ali et al, 2002). The combination therapy of 
OX40L fusion protein and DISC/mGM-CSF virus reported in this study was more effective 
in inhibiting both CT26 and 4T1 s.c tumours than either of the single therapies.  This 
approach may circumvent the limited therapeutic "window" for use of mOX40L as a single 
therapeutic agent, and that combined with DISC/mGM-CSF an enhanced T-cell response can 
be generated.  Thus, DISC/mGM-CSF (given on day 0) might activate naive T-cells that are 
then able to respond to mOX40L (given on day 3). 
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Legends 
Fig 1 In vitro T cell proliferation Enhancement by OX40L and OX86 Antibody 
Balb/c mice were immunised i.p with Staphylococcal enterotoxin B (SEB). Twenty 
four hour later lymph nodes were removed and cultured in vitro with 0.5 μg/ml SEB 
and varying concentrations of murine OX40L, OX86 or human OX40L for 72 hours. 
Murine IgG1 was also included as control (Data not given). Cells were pulsed with 
3H thymidine for the final 6 hours of culture. 
 
Fig 2.  Effect of therapy with OX40L on tumour growth in vivo 
A&B. 1x104 of CT 26 and 4T1 tumour cells were respectively implanted s.c in to two groups 
of 10 Balb/c mice. One group was injected i.p on day 3 and 7 with 250μg of OX40L fusion 
protein. The other group was injected i.p with PBS and used as a control. Animals were 
inspected regularly and their tumour progression was recorded. 
 
Fig 3. Species specificity of OX40 L 
1x104 4T1 cells were implanted s.c in 4 groups of 10 Balb/c mice. On day 3 and 7, mice were 
injected i.p with 250 μg of hOX40L-h IgG or mOX40L-h IgG or mOX40L-m IgG fusion 
protein or PBS. Tumour growth was monitored regularly.  
 
Fig 4. Effect of Dose and Route of OX40L Administration on Tumour Growth In Vivo 
 18
A. Five groups of 10 Balb/c mice were implanted s.c with 1x104 4T1 cells. Two groups were 
given 5 doses of 100 and 250 μg per mouse i. p respectively, while the other 2 groups were 
given 2 doses of 250 and 500 μg respectively. The fifth group was injected i.p with PBS and 
used as control. 
B. Five groups of 10 Balb/c mice were implanted s.c with 1x104 4T1 cells. Four groups were 
given 5 doses of 100 or 250μg per mouse either i.p or i.m, respectively. The fifth group was 
injected i.p with PBS and used as control. 
 
Fig 5. Treatment Initiation time Influences Responses to OX40L Therapy 
Five groups of 10 Balb/c mice were implanted s.c with 1x104 CT26 cells. Therapy with 
100μg OX40L was started i.p on day 0, 3, 6 or 10 for each group respectively. The fifth 
group was given PBS i.p as control. S: number of survivals per group. 
 
Fig 6 Inhibition of Experimental Lung Metastasis by OX40L therapy 
Four groups of 10 Balb/c mice were implanted i.v with 2x104 CT26 cells. On day 3 therapy 
with OX40L fusion protein was initiated. Five doses of 50 or 100 or 250 μg/mouse at 3-4 
days intervals were given for each group respectively.  
 
Fig 7. Combination Therapy of OX40L and DISC/mGM-CSF virus 
A. Four groups of 10 Balb/c mice were implanted s.c with 1x104 4T1 cells. Therapy started 
when tumours reached the size of 0.09-0.36 cm2, which is usually on days 8-10. DISC: mice 
were injected twice at 2 days intervals with 2.5X107 pfu DISC/mGM-CSF virus. OX40L: 
mice were injected i.p with 250 μg/mouse on days 8 and 14. DISC+OX40L: mice were first 
injected intra-tumourally with DISC virus and concomitantly injected i.p with OX40L fusion 
protein as above. PBS: mice were injected intra-tumorally and i.p with PBS as control. 
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B. Four groups of 10 Balb/c mice were implanted with 1x104 CT26 cells and treated with 
DISC virus and OX40L as with 4T1 tumours. 
 
Fig 8. CTL Activity of Splenocytes from Mice Rejected CT26 Tumours Following 
Therapy with OX40L 
Splenocytes from mice with complete regressed tumours following therapy with OX40L 
fusion protein were cultured for 5 days in the presence or absence of the gp70 AH-1 peptide 
(SPS..), or  the non relevant β-gal peptide (TPH..) and tested against CT26 and A20 peptide 
pulsed targets. Reg SPS+CT26: splenocytes cultured with SPS peptide and tested against 
CT26 targets. Reg SPS+A20: splenocytes cultured with SPS peptide and tested against A20 
cells. Reg TPH+CT26: splenocytes cultured with TPH and tested against CT26 cells. Reg 
none+CT26: splenocytes cultured with no peptide and tested against CT26 cells. 
B. Splenocytes were cultured as above but tested against A20 targets pulsed with SPS or TPH 
peptides. 
 
Fig 9. OX40L Therapy in Mice Depleted of CD4+ and CD8+ T cells.  
Treatment of mice with anti-CD4+ or anti-CD8+ monoclonal antibody, given 3 time i.p over a 
period of 1 week, reduced the circulating CD4+ and CD8+ T cells by 95% and 50%, 
respectively as determined by antibody staining and flow cytometery (data not shown; Ali et 
al, 2000). Tumour cells injection and OX40L therapy started on days 4 and 7 after the 
initiation of Ab treatment, respectively. CD4&CD8 Dep: mice depleted of lymphocytes 
receiving OX40L therapy. CD4 Dep: mice depleted of CD4+lymphocytes receiving OX40L 
therapy.  CD8 Dep: mice depleted of CD8+lymphocytes receiving OX40L therapy. Isotype 
Dep: mice were given isotype control Ab and receiving OX40L therapy. Media : Control 
mice receiving media and OX40L therapy. Control: neither depletion nor therapy. 
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